CFG
NBIX icon

Citizens Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Citizens Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$716K Buy
4,249
+995
+31% +$148K 0.01% 541
2026
Q1 		$429K Buy
+3,254
New +$432K 0.01% 582
2020
Q3 		– Sell
-67
Closed -$8K – 675
2020
Q2 		$8K Hold
67
– – ﹤0.01% 807
2020
Q1 		$6K Sell
67
-68
-50% -$6.66K ﹤0.01% 837
2019
Q4 		$15K Buy
+135
New +$14.1K ﹤0.01% 670

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citizens Financial Group's NBIX Position: Q2 2026 in Review

Citizens Financial Group increased its Neurocrine Biosciences (NBIX) stake by 31% in Q2 2026, buying an estimated $148K and bringing the position to 4,249 shares worth $716K. The position accounts for 0.01% of the portfolio, ranked #541.

Citizens Financial Group first reported a position in NBIX in Q4 2019 and has held it in 5 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Citizens Financial Group held 4,249 shares of Neurocrine Biosciences worth $716K as of Q2 2026.
  • Citizens Financial Group bought 995 Neurocrine Biosciences shares in Q2 2026, an estimated $148K.
  • Neurocrine Biosciences made up 0.01% of Citizens Financial Group's portfolio in Q2 2026, its #541 holding.
  • Citizens Financial Group first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 5 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Citizens Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.